Periorificial dermatitis — Viva

Q1: Definition and cardinal sign (2 min)

What is periorificial (perioral) dermatitis? A chronic papulopustular facial dermatitis — acneiform facial eruptions often with an eczematous appearance, with a granulomatous subtype in addition to the classic variant ^{[1] [3]}. State the morphology — grouped, monomorphic, small erythematous to flesh-coloured papules (pustules rare) with scaling on a background of erythema ^{[7] [15] [9]} — and the distribution (the perioral region is the most common site, the periocular and paranasal skin are also affected; the eruption is often bilateral but may be unilateral ^[15]). State the HALLMARK clinical sign — SPARING OF THE VERMILION BORDER: the papules "usually leave a 1-2 mm Grenz zone around the red lips unaffected" ^[9], and "the vermilion border is spared in perioral dermatitis" ^[15]; the lips themselves are unaffected ^[9]. Why is the vermilion border spared? The SIGN is established but the MECHANISM is not — a proposed (unproven) explanation is the vermilion's lack of pilosebaceous follicles; teach the sign as fact and the mechanism as hypothesis.

Q2: Triggers and risk factors (2 min)

List the recognised triggers of periorificial dermatitis, grouped into the STEROIDS mnemonic: (1) Steroids (topical, inhaled, nasal) — the dominant iatrogenic trigger: the strongest evidence supports topical corticosteroid misuse as the principal causative factor ^{[1] [15] [5]}. (2) Toothpaste (fluoridated) — an associated trigger at case-report level ^{[15] [16]}. (3) Emollients — the combined use of moisturizers and foundations, and barrier-disrupting skin-care practices, are identified underlying etiologies ^[15]. (4) Rain of cosmetics — cosmetics and physical sunscreens have been identified as underlying etiologies in some patients ^[15]. (5) OCP / hormonal — hormonal influences are suspected, but oral contraceptive pills have been associated with the IMPROVEMENT of perioral dermatitis: teach hormones as suspected and do not teach OCP as an established trigger ^[15]. (6) Immunosuppression and Idiopathic — the etiology remains incompletely understood ^{[1] [3]}. (7) Demodex mites, with Candida albicans and fusiform bacteria, are the proposed infectious sources ^[15]; Diet — debated. (8) Sunscreens — physical sunscreens with high sun protection factor have been implicated, particularly in children; facemask use and improper CPAP therapy are additional reported triggers ^[15]. Why are women disproportionately affected? The classic demographic is women aged 15 to 45 years (young adult females, 20 to 45) ^{[6] [15] [9]}, and in a 1032-patient series the POD patients were younger and predominantly female ^[14]; the proposed explanation — higher cosmetic, moisturiser and sunscreen use, greater exposure to prescription topical corticosteroids, and hormonal modulation of skin immunity — remains hypothesis, not established fact.

Q3: Pathophysiology and the rebound flare (2 min)

Outline the pathophysiology: (1) Skin barrier dysfunction — "epidermal barrier dysfunction as an underlying main pathogenic factor" ^[6] — is the substrate on which triggers act; current reviews frame pathogenesis around inciting factors, skin barrier dysfunction, inflammation, and the microbiome ^[3]. (2) Trigger exposure — topical steroids have been postulated to influence the microflora of the hair follicle ^[15], and proposed infectious sources include Candida albicans, fusiform bacteria, and Demodex mites ^[15]. (3) Topical corticosteroid — "initially responsive to steroids", the condition often worsens with withdrawal, potentially leading to chronic, recurrent disease or a granulomatous variant ^{[15] [7]}; atrophy is among the most frequent cutaneous adverse effects of topical glucocorticosteroids ^[4], and on withdrawal a rebound flare develops — "the rebound phenomenon usually develops after cessation of previous topical treatment" ^[6]; patients "should be forewarned that the condition will likely worsen until it improves" ^[15]. (4) Tetracyclines act through their anti-inflammatory properties ^[15]; clinically, perifollicular and perivascular inflammation produces the erythematous papules around the mouth, eyes and nose ^[15].

Q4: Differential diagnosis (3 min)

List the differentials and the discriminating features: papulopustular rosacea (inflammatory papules and pustules primarily of the central face including the nose, with accompanying telangiectatic erythema and flushing; many authors view perioral dermatitis as a variant of rosacea, as both respond to the same therapies ^[15]); allergic contact dermatitis (ill-defined scaling macules, patches and plaques with possible lichenification; if POD does not improve with conventional treatment, patch testing should be considered to rule out allergic contact dermatitis from skincare or oral-care products ^[15] — in women with confirmed allergic contact stomatitis, sensitisation is highest for metals (nickel 28.6%, palladium 21.4%, amalgam 10.9%), balsam of Peru (11.4%) and propolis (6.8%) ^[26]); acne vulgaris (adult female acne — inflammatory papules of the chin and jawline — can have a similar distribution ^[15]; persistent acne is the major differential ^[9]); seborrhoeic dermatitis (ill-defined erythematous patches with greasy scale on the eyebrows, glabella, paranasal skin and nasolabial folds ^[15]); demodicosis (infestation defined as at least 5 living mites/cm2 of skin ^[25]; 5 D/cm2 is the normal-threshold boundary on standardized skin surface biopsy ^[20]); lupus miliaris disseminatus faciei / LMDF (epithelioid granulomas with inflammatory cell infiltration and, in some cases, central caseous necrosis; facial involvement mostly around the eyes and on the eyelids ^[21]); perioral sarcoidosis (red-brown papules on the periorificial face, but typically more widespread, with systemic sarcoidosis symptoms ^[15]); angular cheilitis / perlèche (corner-of-mouth fissures + Candida / Staph); granuloma faciale (single plaque + leukocytoclastic vasculitis on biopsy); perioral SCC (single chronic lesion in an older patient; biopsy until proven otherwise). In children the important differentials include atopic and seborrheic dermatosis, pediatric rosacea, juvenile acne, and cutaneous sarcoidosis ^[9]; granulomatous POD differs from sarcoidosis by lymphocytes around the granulomas and absent systemic involvement ^[28]. Which differentials are cannot-miss? Allergic contact dermatitis (clinicians often misdiagnose POD and inappropriately prescribe topical corticosteroids, which worsen the condition over time ^[15]), perioral sarcoidosis, perioral SCC.

Q5: Investigations (2 min)

Periorificial dermatitis is a CLINICAL diagnosis in the typical case — laboratory tests are not helpful and the histology resembles rosacea ^[7]; biopsy or additional testing may be warranted in atypical cases or on lack of response to treatment ^[15]. Investigations are reserved for: (1) atypical morphology or diagnostic uncertainty — punch biopsy; classic histology shows a perifollicular and perivascular lymphohistiocytic inflammatory infiltrate with sparse plasma cells, and follicular spongiosis may be present even though typical dermatitis features are often absent ^[15]; (2) pustular lesions, secondary infection or treatment failure — skin swab for microbiology; (3) vesicles present — HSV PCR to exclude herpetic involvement; (4) lip involvement or new product exposure — patch testing (standard, dental and cosmetic series; dental-material allergens are a documented sensitisation source) ^{[15] [26]}; (5) Demodex suspicion — standardized skin surface biopsy, with at least 5 living mites/cm2 defining infestation ^{[25] [20]}; (6) refractory or recurrent disease — metabolic and infective screening. Histology of the granulomatous variant (FACE): dermal epithelioid granulomas and giant cells ^[15], an "upper dermal and perifollicular granulomatous infiltrate" ^[13].

Q6: Management — the staged ladder (3 min)

Outline the staged ladder. (1) ZERO THERAPY — in mild perioral dermatitis "zero therapy" is the treatment of choice ^[6]: discontinue the topical corticosteroid (discontinuation of steroid application is a primary treatment recommendation ^[15]), weaning medium- to high-potency steroids slowly via a low-potency steroid (eg, hydrocortisone cream) ^[15]; stop other topicals and avoid fluorinated toothpaste, heavy cosmetics and unnecessary skincare products ^[15]; COUNSEL on the rebound flare — it develops after cessation of previous topical treatment and the condition will likely worsen until it improves ^{[15] [6]}. (2) TOPICAL ANTI-INFLAMMATORY for mild-moderate disease: first-line options are metronidazole cream or gel (the 0.75% gel has been studied in children), clindamycin lotion or gel, erythromycin gel, topical sulfur preparations, and azelaic acid gel ^[15]; topical calcineurin inhibitors — pimecrolimus cream or tacrolimus ointment — can also be effective ^[15] and represent effective treatment choices with good evidence ^[5]; note the systematic review found pimecrolimus may improve severity slightly at 4 weeks (MD -0.49, 95% CI -1.02 to 0.04; low certainty) ^[2] while azelaic acid gel may result in no change in severity after 6 weeks ^[2]. (3) ORAL TETRACYCLINE for moderate-severe or refractory disease ^{[5] [9]} — "oral tetracycline reveals the best valid evidence" ^[5] and is the best validated choice in more severe disease, in a subantimicrobial dose until complete remission is achieved ^[6]; dosing: tetracycline 250-500 mg twice a day, doxycycline 100 mg once or twice a day, or minocycline 100 mg once or twice a day, "for an 8 to 12 week tapering course", with topical therapies used concurrently ^[15]. When tetracyclines are contraindicated (children younger than 8 years, pregnancy, nursing): erythromycin 250-500 mg daily ^[15].

Q7: Granulomatous variant (FACE) (2 min)

Describe the Facial Afro-Caribbean Childhood Eruption (FACE / childhood granulomatous periorificial dermatitis, CGPD): "a distinctive granulomatous form of perioral dermatitis" ^[13] occurring in prepubertal children ^[28]. Age: POD is documented in children as young as 3 months ^[7]; the largest TCI cohort (132 patients) had a median age at diagnosis of 4.2 years (interquartile range 2.3-8.2) ^[8]. Sex: POD overall shows a slight predominance in girls ^[7], while the granulomatous form "is more common in childhood and affects mostly prepubescent boys" ^[6]. Morphology: monomorphic small erythematous to flesh-coloured papules around the mouth, nose and eyes; pustules are rare ^{[13] [7]}. Distribution: perinasal skin, nostrils and eyelids can be involved, while extrafacial manifestations are rare ^{[9] [13]}. Triggers: many children have had recent exposure to a topical — less commonly an inhaled or systemic — corticosteroid ^{[7] [24]}. Histology: "upper dermal and perifollicular granulomatous infiltrate" ^[13]. Course: "typically persists for several months but resolved without scarring" ^[13]; it is "ultimately self-limited" and the correct diagnosis is important to minimize treatment ^[28]; it can be confused with sarcoidosis, infection, and granulomatous rosacea but contains lymphocytes around the granulomas and lacks the systemic involvement seen in sarcoidosis ^[28]. Treatment: topical calcineurin inhibitors — complete response in 68.8% of patients treated with TCI alone, with adverse events rare and mild ^[8]; topical metronidazole has been successful in children ^[7]; for paediatric patients with extrafacial lesions or more severe disease, oral antibiotics depending on age — tetracycline, doxycycline, minocycline, azithromycin, and erythromycin ^[7] — or clarithromycin for moderate-to-severe and refractory disease (95.4% [41/43] cleared at 6 months, median 10-week course) ^[23]. Oral tetracycline may not be suitable under 8 years ^[5] and in infants and preschoolers tetracyclines should be avoided, since they can affect the calcification of bones and teeth and lead to permanent tooth discolouration ^[9].

Q8: Special populations (2 min)

List the special-population deltas: children — oral tetracycline may not be suitable under 8 years ^[5] and tetracyclines are avoided in infants and preschoolers (calcification of bones and teeth, permanent tooth discolouration) ^[9]; there are no randomised controlled trials in this age group, and topical metronidazole or erythromycin plus oral erythromycin are most used ^[9]; pregnancy — tetracyclines are class D, contraindicated in pregnancy and in children under 8 years ^[17] (risk of permanent tooth discolouration and possible impact on fetal bone formation ^[18]); isotretinoin — a therapeutic option only for patients refractory to all standard therapies ^[6] — is a potent teratogen and contraindicated in pregnancy ^[19]; oral erythromycin 250-500 mg daily is the standard alternative when an oral agent is needed ^[15]; elderly — rosacea overlap; topical steroid misuse history often long; review co-medication with tetracyclines; immunocompromised — consider demodicosis (standardized skin surface biopsy; at least 5 living parasites/cm2 defines infestation ^[25]), candidiasis, atypical mycobacteria, deep fungi; biopsy if refractory; skin of colour — post-inflammatory hyperpigmentation is a major concern; azelaic acid is dual-action; the granulomatous variant (facial Afro-Caribbean childhood eruption ^[13]) is over-represented; patients using inhaled / nasal corticosteroids — recognised triggers ^[15]; rinse the mouth and wash the face after each actuation, use a spacer, and consider a non-steroid preventer.

Q9: Complications, prognosis and safety-net (2 min)

Complications: post-inflammatory hyperpigmentation (especially in skin of colour); emotional distress due to the chronicity of the disease and poor quality of life due to sometimes disfiguring lesions on the face; scarring may occur with the lupoid variant ^[15]; TSDF — atrophy is among the most frequent adverse effects of topical glucocorticosteroids, with hypertrichosis and pigmentation alterations less frequent ^[4]; iatrogenic harm from misdiagnosis — clinicians often misdiagnose perioral dermatitis and inappropriately prescribe topical corticosteroids, which worsen the condition over time ^[15]. Prognosis: the rash may resolve completely after discontinuation of an offending agent, including topical steroids and skincare products, but is frequently a chronic relapsing condition requiring long-term treatment ^[15]; oral tetracycline benefit may appear from day 20 onwards (low certainty) ^[2]; the oral course is an 8-12 week taper ^[15]; topical therapies may not show peak efficacy until 3 months of daily treatment ^[15]; the childhood granulomatous variant persists several months and resolves without scarring ^[13]. Recurrence: chronic, recurrent course recognised — the condition is initially steroid-responsive and worsens with withdrawal, particularly if topical steroids are restarted ^[15]. Disposition: outpatient; primary care providers and dermatologists are typically responsible for diagnosing and initiating treatment ^[15]. Follow-up: week 0, 4, 8, 12, 24. Safety-net advice: discontinue all topical steroids on the face, including over-the-counter products, weaning medium- to high-potency steroids via low-potency hydrocortisone cream ^[15]; avoid fluorinated toothpaste, heavy cosmetics and unnecessary skincare products ^[15]; expect a temporary worsening — a rebound flare — after stopping steroids, with a realistic treatment timeline of several weeks to months and possible chronic or recurrent symptoms ^[15]; return if worsening or no response despite adherence.

Q10: Regional deltas and evidence (2 min)

State the evidence base: JEADV 2022 systematic review ^[2] (11 studies, 733 participants; the body of evidence is low and very low certainty for important outcomes): oral tetracycline may improve physician-reported severity from day 20 onwards (low certainty); pimecrolimus may improve physician-reported severity slightly after 4 weeks (MD -0.49, 95% CI -1.02 to 0.04); azelaic acid gel may result in no change in physician- or patient-reported severity after 6 weeks; adverse effects may include abdominal discomfort, facial dryness and pruritus ^[2]; no trial evidence was identified for metronidazole, ivermectin, isotretinoin, or "zero therapy". JAAD 2026 review ^[3] — no therapies are specifically FDA-approved for POD; etiology remains incompletely understood; pathogenesis is discussed via inciting factors, skin barrier dysfunction, inflammation, and the microbiome; management is skincare, topical, and systemic therapies. US retrospective paediatric TCI cohort ^[8] — topical calcineurin inhibitors effective and well tolerated (68.8% complete response with TCI alone; adverse events rare and mild). India cross-sectional study ^[22] — topical steroid and "fairness cream" abuse drives topical steroid-damaged/dependent face (64.6% non-prescription use in a consecutive cohort, most commonly recommended by pharmacists); the authors call for stricter regulation of potent steroids. Quote the STEROIDS mnemonic for triggers and the ZERO STOP mnemonic for initial management. Note: no UK (NICE CKS is UK-licensed access only), Australasian, or region-specific POD guideline was verifiable in this review — attribute the ladder to ^[6] and ^[5], not to a national body.

References24ShowHide

1. [1]Searle T, Ali FR, Al-Niaimi F. Perioral dermatitis: Diagnosis, proposed etiologies, and management J Cosmet Dermatol, 2021.PMID 33751778
2. [2]Gray NA, Tod B, Rohwer A, et al. Pharmacological interventions for periorificial (perioral) dermatitis in children and adults: a systematic review J Eur Acad Dermatol Venereol, 2022.PMID 34779023
3. [3]Acevedo-Fontanez LA, Sánchez-Feliciano A, Ershadi S, et al. Periorificial dermatitis: Pathophysiology, diagnosis, and management J Am Acad Dermatol, 2026.PMID 41197738
4. [4]Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids J Am Acad Dermatol, 2006.PMID 16384751
5. [5]Tempark T, Shwayder TA. Perioral dermatitis: a review of the condition with special attention to treatment options Am J Clin Dermatol, 2014.PMID 24623018
6. [6]Mokos ZB, Kummer A, Mosler EL, et al. Perioral dermatitis: still a therapeutic challenge Acta Clin Croat, 2015.PMID 26415314
7. [7]Kellen R, Silverberg NB. Pediatric periorificial dermatitis Cutis, 2017.PMID 29360899
8. [8]Ollech A, Yousif R, Kruse L, et al. Topical calcineurin inhibitors for pediatric periorificial dermatitis J Am Acad Dermatol, 2020.PMID 32032693
9. [9]Chiriac A, Chiriac AE, Madke B, et al. Periorificial dermatitis in infants and preschoolers - a narrative review Eur J Pediatr, 2025.PMID 39825187
10. [13]Kim YJ, Shin JW, Lee JS, et al. Childhood granulomatous periorificial dermatitis Ann Dermatol, 2011.PMID 21909215
11. [14]Hoepfner A, Marsela E, Clanner-Engelshofen BM, et al. Rosacea and perioral dermatitis: a single-center retrospective analysis of the clinical presentation of 1032 patients J Dtsch Dermatol Ges, 2020.PMID 32469453
12. [15]Tolaymat L, Syed HA, Hall MR. Perioral Dermatitis StatPearls [Internet], 2026.PMID 30247843
13. [16]Peters P, Drummond C. Perioral dermatitis from high fluoride dentifrice: a case report and review of literature Aust Dent J, 2013.PMID 23981221
14. [17]Cross R, Ling C, Day NP, et al. Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation? Expert Opin Drug Saf, 2016.PMID 26680308
15. [18]Smith GN, Gemmill I, Moore KM. Management of tick bites and lyme disease during pregnancy J Obstet Gynaecol Can, 2012.PMID 23231847
16. [19]Ivask M, Kurvits K, Uusküla M, et al. Compliance with Pregnancy Prevention Recommendations for Isotretinoin Following the Amendment of the European Union Pregnancy Prevention Program: A Repeat Study in Estonia Drugs Real World Outcomes, 2024.PMID 37462893
17. [20]Forton F, Seys B, Marchal JL, et al. Demodex folliculorum and topical treatment: acaricidal action evaluated by standardized skin surface biopsy Br J Dermatol, 1998.PMID 9580800
18. [21]Nasimi M, Bandani S, Kamyab K, et al. Clinical and Histopathological Insights Into Lupus Miliaris Disseminatus Faciei: A Review of 70 Cases J Cutan Pathol, 2025.PMID 39945109
19. [22]Sethi P, Maheshwari K, Arora E, et al. Topical Steroid and Fairness Cream Abuse in Facial Dermatoses: A Cross-Sectional Study at a Tertiary Care Center in Western Uttar Pradesh Cureus, 2026.PMID 41959968
20. [23]Xiao Y, He J, Chen A, et al. Management of childhood granulomatous periorificial dermatitis with clarithromycin: A retrospective cohort study JAAD Int, 2025.PMID 41079392
21. [24]Jagdeo M, Keddy-Grant J. Treatment-resistant granulomatous periorificial dermatitis in a 14-year-old female: Resolution after oral isotretinoin and methotrexate - A case report SAGE Open Med Case Rep, 2026.PMID 42111043
22. [25]Aksu Arıca D, Ozturk Topcu T, Baykal Selçuk L, et al. Assessment of demodex presence in acne-like rash associated with cetuximab Cutan Ocul Toxicol, 2017.PMID 27802779
23. [26]Forkel S, Schubert S, Corvin L, et al. Contact allergies to dental materials in patients Br J Dermatol, 2024.PMID 38123140
24. [28]Lucas CR, Korman NJ, Gilliam AC. Granulomatous periorificial dermatitis: a variant of granulomatous rosacea in children? J Cutan Med Surg, 2009.PMID 19298782